Literature DB >> 9337833

Lung surfactant in a cystic fibrosis animal model: increased alveolar phospholipid pool size without altered composition and surface tension function in cftrm1HGU/m1HGU mice.

W Bernhard1, J Y Wang, T Tschernig, B Tümmler, H J Hedrich, H von der Hardt.   

Abstract

BACKGROUND: Progressive pulmonary dysfunction is a characteristic symptom of cystic fibrosis (CF) and is associated with functional impairment and biochemical alterations of surfactant phospholipids in the airways. However, the fundamental question of whether surfactant alterations in the CF lung are secondary to the pulmonary damage or are present before initiation of chronic infection and inflammation has yet to be resolved in patients with cystic fibrosis but can now be addressed in CF mice that exhibit the basic defect in the airways. A study was therefore undertaken to investigate the pool sizes, composition, and function of lung surfactant in the non-infected cftrm1HGU/m1HGU mouse.
METHODS: The amount and composition of phospholipid classes and phosphatidylcholine molecular species were determined in bronchoalveolar lavage (BAL) fluid and lavaged lungs by high performance liquid chromatography (HPLC). Surfactant protein A (SP-A) levels in BAL fluid were determined by ELISA and surfactant for functional measurements was isolated from BAL fluid by differential ultracentrifugation. Equilibrium and minimal surface tension of surfactant was assessed by the pulsating bubble surfactometer technique. MF1, BALB/c, C57/BL6, and C3H/He mice served as controls.
RESULTS: BAL fluid of cftrm1HGU/m1HGU mice contained 1.02 (95% confidence interval (CI) 0.89 to 1.16) mumol phospholipid and 259 (239 to 279) ng SP-A. BAL fluid of MF1, BALB/c, C57BL/6, and C3H/He mice contained 0.69 (0.63 to 0.75), 0.50 (0.42 to 0.57), 0.52 (0.40 to 0.64), and 0.45 (0.27 to 0.63) mumol phospholipid, respectively. After correction for the different body weights of mouse strains, phospholipid levels in BAL fluid of cftrm1HGU/m1HGU mice were increased by 64 (52 to 76)%, 60 (39 to 89)%, 72 (45 to 113)%, and 92 (49 to 163)%, respectively, compared with controls. The amount of SP-A in BAL fluid and the composition of phospholipid as well as phosphatidylcholine molecular species in BAL fluid and lung tissue was unchanged in cftrm1HGU/m1HGU mice compared with controls. The increase in phospholipids in BAL fluid of cftrm1HGU/m1HGU mice resulted from an increased fraction of large aggregates which exhibited normal surface tension function.
CONCLUSION: In cftrm1HGU/m1HGU mice surfactant homeostasis is perturbed by an increased phospholipid pool in the alveolar compartment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9337833      PMCID: PMC1758618          DOI: 10.1136/thx.52.8.723

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  21 in total

Review 1.  Scientific advances in cystic fibrosis.

Authors:  C R Marino; F S Gorelick
Journal:  Gastroenterology       Date:  1992-08       Impact factor: 22.682

2.  A rapid method of total lipid extraction and purification.

Authors:  E G BLIGH; W J DYER
Journal:  Can J Biochem Physiol       Date:  1959-08

3.  Phosphorus assay in column chromatography.

Authors:  G R BARTLETT
Journal:  J Biol Chem       Date:  1959-03       Impact factor: 5.157

Review 4.  Surfactant and the adult respiratory distress syndrome.

Authors:  J F Lewis; A H Jobe
Journal:  Am Rev Respir Dis       Date:  1993-01

5.  Respiratory mucous secretions in patients with cystic fibrosis: relationship between levels of highly sulfated mucin component and severity of the disease.

Authors:  K V Chace; D S Leahy; R Martin; R Carubelli; M Flux; G P Sachdev
Journal:  Clin Chim Acta       Date:  1983-08-15       Impact factor: 3.786

6.  Cystic fibrosis in the mouse by targeted insertional mutagenesis.

Authors:  J R Dorin; P Dickinson; E W Alton; S N Smith; D M Geddes; B J Stevenson; W L Kimber; S Fleming; A R Clarke; M L Hooper
Journal:  Nature       Date:  1992-09-17       Impact factor: 49.962

7.  Relationships between the lipid content and the rheological properties of airway secretions in cystic fibrosis.

Authors:  C Galabert; J Jacquot; J M Zahm; E Puchelle
Journal:  Clin Chim Acta       Date:  1987-04-30       Impact factor: 3.786

8.  Localization of cystic fibrosis transmembrane conductance regulator mRNA in human fetal lung tissue by in situ hybridization.

Authors:  P B McCray; C L Wohlford-Lenane; J M Snyder
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

9.  Mouse alveolar surfactant: characterization of subtypes prepared by differential centrifugation.

Authors:  M Oulton; J MacDonald; D T Janigan; G T Faulkner
Journal:  Lipids       Date:  1993-08       Impact factor: 1.880

Review 10.  The surfactant system of the adult lung: physiology and clinical perspectives.

Authors:  H Hamm; H Fabel; W Bartsch
Journal:  Clin Investig       Date:  1992-08
View more
  10 in total

1.  Regulation of Macrophage Foam Cell Formation During Nitrogen Mustard (NM)-Induced Pulmonary Fibrosis by Lung Lipids.

Authors:  Alessandro Venosa; Ley Cody Smith; Alexa Murray; Tanvi Banota; Andrew J Gow; Jeffrey D Laskin; Debra L Laskin
Journal:  Toxicol Sci       Date:  2019-12-01       Impact factor: 4.849

2.  MALDI imaging MS of phospholipids in the mouse lung.

Authors:  Karin A Zemski Berry; Bilan Li; Susan D Reynolds; Robert M Barkley; Miguel A Gijón; Joseph A Hankin; Peter M Henson; Robert C Murphy
Journal:  J Lipid Res       Date:  2011-04-20       Impact factor: 5.922

3.  Pseudomonas aeruginosa directly shunts β-oxidation degradation intermediates into de novo fatty acid biosynthesis.

Authors:  Yanqiu Yuan; Jennifer A Leeds; Timothy C Meredith
Journal:  J Bacteriol       Date:  2012-06-29       Impact factor: 3.490

4.  Lipidomic characterization and localization of phospholipids in the human lung.

Authors:  Karin A Zemski Berry; Robert C Murphy; Beata Kosmider; Robert J Mason
Journal:  J Lipid Res       Date:  2017-03-09       Impact factor: 5.922

5.  In vivo evidence of Pseudomonas aeruginosa nutrient acquisition and pathogenesis in the lungs of cystic fibrosis patients.

Authors:  Mike S Son; Wallace J Matthews; Yun Kang; David T Nguyen; Tung T Hoang
Journal:  Infect Immun       Date:  2007-08-27       Impact factor: 3.441

6.  Low-concentration ozone reacts with plasmalogen glycerophosphoethanolamine lipids in lung surfactant.

Authors:  Kelly M Wynalda; Robert C Murphy
Journal:  Chem Res Toxicol       Date:  2010-01       Impact factor: 3.739

7.  Functional characterization of Yersinia pestis aerobic glycerol metabolism.

Authors:  Stephan P Willias; Sadhana Chauhan; Vladimir L Motin
Journal:  Microb Pathog       Date:  2014-09-16       Impact factor: 3.738

8.  Blocking phosphatidylcholine utilization in Pseudomonas aeruginosa, via mutagenesis of fatty acid, glycerol and choline degradation pathways, confirms the importance of this nutrient source in vivo.

Authors:  Zhenxin Sun; Yun Kang; Michael H Norris; Ryan M Troyer; Mike S Son; Herbert P Schweizer; Steven W Dow; Tung T Hoang
Journal:  PLoS One       Date:  2014-07-28       Impact factor: 3.240

9.  Elucidating the Pseudomonas aeruginosa fatty acid degradation pathway: identification of additional fatty acyl-CoA synthetase homologues.

Authors:  Jan Zarzycki-Siek; Michael H Norris; Yun Kang; Zhenxin Sun; Andrew P Bluhm; Ian A McMillan; Tung T Hoang
Journal:  PLoS One       Date:  2013-05-29       Impact factor: 3.240

10.  Transient in utero disruption of cystic fibrosis transmembrane conductance regulator causes phenotypic changes in alveolar type II cells in adult rats.

Authors:  Ashraf Gad; Delon L Callender; Erin Killeen; Joseph Hudak; Malgosia A Dlugosz; Janet E Larson; J Craig Cohen; Avinash Chander
Journal:  BMC Cell Biol       Date:  2009-03-31       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.